Liles et al. demonstrated that the FXR agonist GS-9674 reduced serum transaminases, liver fibrosis, and steatosis in high-fat, cholesterol, and sugar diet-induced mouse NAFLD [106]. Here, NR1H4 is linked to steatosis.